Ritika-Mahmuda Ahmed

Ritika-Mahmuda Ahmed

Auto-generated profile, based on publicly available information

Ritika-Mahmuda Ahmed

UCL Cancer Institute, University College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GZGeorgia Zoumpoulidou
Georgia Zoumpoulidou
CACarlos Alvarez-Mendoza
Carlos Alvarez-Mendoza
CMCaterina Mancusi
Caterina Mancusi
RARitika-Mahmuda Ahmed
Ritika-Mahmuda Ahmed
MDMilly Denman
Milly Denman
Sibylle MittnachtSibylle Mittnacht
Sibylle Mittnacht
Loss-of-function mutations in the RB1 tumour suppressor are key drivers in cancer, including osteosarcoma. RB1 loss-of-function compromises genome-maintenance and hence could yield vulnerability to therapeutics targeting such processes. Here we demonstrate selective hypersensitivity to clinically-approved inhibitors of Poly-ADP-Polymerase1,2 inhibitors (PARPi) in RB1-defective cancer cells, including an extended panel of osteosarcoma-derived lines. PARPi treatment results in extensive cell death in RB1-defective backgrounds and prolongs survival of mice carrying human RB1-defective osteosarcoma grafts. PARPi sensitivity is not associated with canonical homologous recombination defect (HRd) signatures that predict PARPi sensitivity in cancers with BRCA1,2 loss, but is accompanied by rapid activation of DNA replication checkpoint signalling, and active DNA replication is a prerequisite for sensitivity. Importantly, sensitivity in backgrounds with natural or engineered RB1 loss surpasses that seen in BRCA-mutated backgrounds where PARPi have established clinical benefit. Our work provides evidence that PARPi sensitivity extends beyond cancers identifiable by HRd and advocates PARP1,2 inhibition as a personalised strategy for RB1-mutated osteosarcoma and other cancers.

5 February 2021 in Research Square
Verified
Preprint
Open access
PDF file
GZGeorgia Zoumpoulidou
Georgia Zoumpoulidou
CMCarlos Alvarez Mendoza
Carlos Alvarez Mendoza
CMCaterina Mancusi
Caterina Mancusi
RARitika-Mahmuda Ahmed
Ritika-Mahmuda Ahmed
MDMilly Denman
Milly Denman
Sibylle MittnachtSibylle Mittnacht
Sibylle Mittnacht
Loss-of-function mutations in the RB1 tumour suppressor are key drivers in cancer, including osteosarcoma. RB1 loss-of-function compromises genome-maintenance and hence could yield vulnerability to therapeutics targeting such processes. Here we demonstrate selective hypersensitivity to clinically-approved inhibitors of Poly-ADP-Polymerase1,2 inhibitors (PARPi) in RB1-mutated cancer cells including an extended panel of osteosarcoma-derived lines. PARPi treatment results in extensive cell death in RB1-mutated backgrounds and prolongs survival of mice carrying human RB1-mutated osteosarcoma grafts. PARPi sensitivity is not associated with canonical homologous recombination defect (HRd) signatures, which predict PARPi sensitivity in cancers with BRCA1,2 loss, but is accompanied by rapid activation of DNA replication checkpoint signalling, and active DNA replication is a prerequisite for sensitivity. Importantly, sensitivity in backgrounds with natural or engineered RB1 loss surpasses that seen in BRCA-mutated backgrounds where PARPi have established clinical benefit. Our work provides evidence that PARPi sensitivity extends beyond cancers identifiable by HRd and advocates PARP1,2 inhibition as a novel, personalised strategy for RB1-mutated osteosarcoma and other cancers.